Carvedilol protects against apoptotic cell death induced by cisplatin in renal tubular epithelial cells

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 75, Issue 16-17, 2012, Pages 981-990

  Carvalho Rodrigues, M A ^a   Gobe, G ^b   Santos, N A G ^a   Santos, A C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; CASPASE 3; CASPASE 9; CISPLATIN;

APOPTOSIS; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; KIDNEY TUBULE CELL; MITOCHONDRION; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL PROTECTION;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAZOLES; CASPASE 3; CASPASE 9; CELL LINE; CISPLATIN; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KIDNEY TUBULES; PROPANOLAMINES;

EID: 84864874061     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2012.696512     Document Type: Conference Paper

References (48)

1. Ajith, T. A., Abhishek, G., Roshny, D., and Sudheesh, N. P. 2009. Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp. Toxicol. Pathol. 61: 565-71.
2. Ali, B. H., and Al Moundhri, M. S. 2006. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research. Food Chem. Toxicol. 44: 1173-83.
3. Allan, L. A., and Clarke, P. R. 2009. Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation. FEBS J. 276: 6063-73.
4. Baek, S. M., Kwon, C. H., Kim, J. H.,Woo, J. S., Jung, J. S., and Kim, Y. K. 2003. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J. Lab. Clin. Med. 142: 178-86. (Pubitemid 37260471)
5. Baliga, R., Ueda, N.,Walker, P. D., and Shah, S. V. 1999. Oxidant mechanisms in toxic acute renal failure. Drug Metab. Rev. 31: 971-97.
6. Bratton, S. B., and Salvesen, G. S. 2010. Regulation of the Apaf-1-caspase-9 apoptosome. J. Cell. Sci. 123: 3209-14.
7. Cullen, K. J., Yang, Z., Schumaker, L., and Guo, Z. 2007. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 39: 43-50. (Pubitemid 46877172)
8. Cvitkovic, E. 1998. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat. Rev. 24: 265-81. (Pubitemid 28488281)
9. Davidson, K., Percy, C., Rennick, A. J., Pat, B. K., Li, J., Nicol, D., Johnson, D. W., and Gobe, G. C. 2005. Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. Nephron. Exp. Nephrol. 99: e112-e120.
10. Dickey, D. T., Wu, Y. J., Muldoon, L. L., and Neuwelt, E. A. 2005. Protection against cisplatin-induced toxicities by Nacetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J. Pharmacol. Exp. Ther. 314: 1052-58. (Pubitemid 41205968)
11. Do Amaral, C. L., Francescato, H. D., Coimbra, T. M., Costa, R. S., Darin, J. D., Antunes, L. M., and Bianchi Mde, L. 2008. Resveratrol attenuates cisplatin-induced nephrotoxicityin rats. Arch. Toxicol. 82: 363-70.
12. Eastman, A. 1999. The mechanism of action of cisplatin: From adducts to apoptosis. I. In Cisplatin: Chemistry and Biochemistry of a leading anticancer drug, ed. E. Lippert, vol. B., 111-35. New York, NY: Wiley-VCH.
13. Francescato, H. D., Coimbra, T.M., Costa, R. S., and Bianchi Mde, L. 2004. Protective effect of quercetin on the evolution of cisplatininduced acute tubular necrosis. Kidney Blood Pressure Res. 27: 148-58. (Pubitemid 39140424)
14. Feuerstein, G. Z., and Ruffolo, R. R., Jr. 1995. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J. 16(suppl F): 38-42.
15. Hanigan, M. H., and Devarajan, P. 2003. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. 1: 47-61.
16. Kaushal, G.P., Kaushal, V., Hong, X., and Shah, S. V. 2001. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 60: 1726-36. (Pubitemid 32999977)
17. Kramer, J. H., and Weglicki, W. B. 1996. A hydroxylated analog of the betaadrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radical Biol. Med. 21: 813-25. (Pubitemid 26365277)
18. Kroning, R., Lichtenstein, A. K., and Nagami, G. T. 2000. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother. Pharmacol. 45: 43-49. (Pubitemid 30099714)
19. Kruidering, M., Van de Water, B., de Heer, E., Mulder, G. J., and Nagelkerke, J. F. 1997. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 280: 638-49. (Pubitemid 27171323)
20. Lau, A. H. 1999. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int. 56: 1295-98. (Pubitemid 29451234)
21. Lieberthal, W., Triaca, V., and Levine, J. 1996. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol. 270: F700-8.
22. Lieberthal, W., Menza, S. A., and Levine, J. S. 1998. Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am. J. Physiol. 274: F315-27.
23. Marina, N., Chang, K. W., Malogolowkin, M., London, W. B., Frazier, A. L., Womer, R. B., Rescorla, F., Billmire, D. F., Davis, M. M., Perlman, E. J., Giller, R., Lauer, S. J., and Olson, T. A. 2005. Amifostine does not protect against the ototoxicity of highdose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: A Children's Oncology Group study. Cancer 104: 841-47. (Pubitemid 41113686)
24. Matsushima, H., Yonemura, K., Ohishi, K., and Hishida, A. 1998. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 131: 518-26. (Pubitemid 28278570)
25. Megyesi, J., Safirstein, R. L., and Price, P. M. 1998. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J. Clin. Invest. 101: 777-82. (Pubitemid 28096074)
26. Morais, C., Pat, B., Gobe, G., Johnson, D. W., and Healy, H. 2006. Pyrrolidine dithiocarbamate exerts anti-proliferative and proapoptotic effects in renal cell carcinoma cell lines. Nephrol. Dial. Transplant. 21: 3377-88. (Pubitemid 44817085)
27. Mukhopadhyay, P., Horvath, B., Zsengeller, Z., Zielonka, J., Tanchian, G., Holovac, E., Kechrid, M., Patel, V., Stillman, I. E., Parikh, S. M., Joseph, J., Kalyanaraman, B., and Pacher, P. 2012. Mitochondrialtargeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radical Biol. Med. 52:497-506.
28. Noguchi, N., Nishino, K., and Niki, E. 2000. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol. 59: 1069-76. (Pubitemid 30110499)
29. Pabla, N., and Dong, Z. 2008. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73: 994-1007. (Pubitemid 351543900)
30. Pauschinger, M., Rutschow, S., Chandrasekharan, K., Westermann, D., Weitz, A., Peter Schwimmbeck, L., Zeichhardt, H., Poller, W., Noutsias, M., Li, J., Schultheiss, H. P., and Tschope, C. 2005. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur. J. Heart Fail. 7: 444-52. (Pubitemid 40732970)
31. Ramesh, G., and Reeves, W. B. 2003. TNFR2-mediated apoptosis and necrosis in cisplatininduced acute renal failure. Am. J. Physiol. Renal. Physiol. 285: F610-18. (Pubitemid 37140245)
32. Rodrigues, M. A., Rodrigues, J. L., Martins, N. M., Barbosa, F., Curti, C., Santos, N. A., and Santos, A. C. 2010. Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion 10: 46-53.
33. Rodrigues, M. A., Rodrigues, J. L., Martins, N. M., Barbosa, F., Curti, C., Santos, N. A., and Santos, A. C. 2011. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem. Biol. Interact. 189: 45-51.
34. Santos, N. A., Catao, C. S., Martins, N. M., Curti, C., Bianchi, M. L., and Santos, A. C. 2007. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidneymitochondria. Arch. Toxicol. 81: 495-504. (Pubitemid 47012464)
35. Santos, N. A., Bezerra, C. S., Martins, N. M., Curti, C., Bianchi, M. L., and Santos, A. C. 2008. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother. Pharmacol. 61: 145-55. (Pubitemid 47512636)
36. Sastry, J., and Kellie, S. J. 2005. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol. 22: 441-45. (Pubitemid 40993608)
37. Schenellmann, R. G. 2001. Toxic responses of the kidney. In Casarett & Doull's toxicology. The basic science of poisons, ed. C. D. Klaassen, 291-514. New York, NY: McGraw-Hill.
38. Shermann, S. E., and Lippard, S. J. 1987. Structural aspectsof platinum anticancer drug interaction with DNA. Chem. Rev. 87: 1153-81.
39. Somani, S. M., Husain, K., Whitworth, C., Trammell, G. L., Malafa, M., and Rybak, L. P. 2000. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: Antioxidant defense system. Pharmacol. Toxicol. 86: 234-41. (Pubitemid 30333651)
40. Stafylas, P. C., and Sarafidis, P. A. 2008. Carvedilol in hypertension treatment. Vasc. Health Risk Manage. 4: 23-30. (Pubitemid 351460844)
41. Stennicke, H. R., Deveraux, Q. L., Humke, E. W., Reed, J. C., Dixit, V. M., and Salvesen, G. S. 1999. Caspase-9 can be activated without proteolytic processing. J. Biol. Chem. 274: 8359-62. (Pubitemid 29164620)
42. Tarladacalisir, Y.T., Kanter, M., and Uygun, M. 2008. Protective effects of vitamin C on cisplatin-induced renal damage: A light and electron microscopic study. Renal Failure 30: 1-8.
43. Turrens, J. F. 2003. Mitochondrial formation of reactive oxygen species. J. Physiol. 552: 335-44. (Pubitemid 37321833)
44. Ueda, N., Kaushal, G. P., and Shah, S. V. 2000. Apoptotic mechanisms in acute renal failure. Am. J. Med. 108: 403-15. (Pubitemid 30162959)
45. Wang, D., and Lippard, S. J. 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4: 307-20. (Pubitemid 41130944)
46. Watanabe, K., Ohta, Y., Nakazawa, M., Higuchi, H., Hasegawa, G., Naito, M., Fuse, K., Ito, M., Hirono, S., Tanabe, N., Hanawa, H., Kato, K., Kodama, M., and Aizawa, Y 2000. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br. J. Pharmacol. 130: 1489-95. (Pubitemid 30611923)
47. Wolf, B. B., and Green, D. R. 1999. Suicidal tendencies: Apoptotic cell death by caspase family proteinases. J. Biol. Chem. 274: 20049-52.
48. Yao, X., Panichpisal, K., Kurtzman, N., and Nugent, K. 2007. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci. 334: 115-24. (Pubitemid 47262919)